We have attached herewith Investor Presentation as per Regulation 30 of SEBI (LODR) Regulation, 2015. Kindly take the same on your record. Thank you.

October 30, 2026 To, To, Listing Department, The National Stock Exchange of India BSE Limited Ltd. Phiroze Jeejeebhoy Towers, The Listing Department Dalal Street, Exchange Plaza, Mumbai – 400 001 Bandra – Kurla Complex, Ref: BSE Scrip Code: 544497 Mumbai – 400051, NSE Scrip Code: AHCL Subject: Investor Presentation – Q2 FY26-27 Dear Sir/Madam, Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the investor presentation, which is also uploaded on our website. The same can be accessed through the link below: www.anlon.in You are requested to take the above information on your record. Thanking You. Yours Faithfully, For ANLON HEALTHCARE LIMITED PUNITKUMAR RASADIA MANAGING DIRECTOR DIN: 06696258 ANLON HEALTHCARE LIMITED CIN No.: L24230GJ2013PLC077543 REGISTERED OFFICE: 101/102, Silver Coin Complex, Opp. Crystal Mall, Kalawad Road, Rajkot-360005, Gujarat (INDIA) PHONE NO.: +91-7069690081/82 | Email: info@anlonhealthcare.com | www.anlon.in Anlon Healthcare Ltd Building a Stronger, Smarter Complete Pharma Value Chain Investor Presentation September 2026 Disclaimer This presentation and the accompanying slides (the “Presentation”), which have been prepared by Anlon Healthcare Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company. This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded. Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company’s ability to successfully implement its strategy, the Company’s future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company’s market preferences and its exposure to market risks, as well as other risks. The Company’s actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections. All Maps used in the presentation are not to scale. All data, information, and maps are provided "as is" without warranty or any representation of accuracy, timeliness or completeness. Investor Presentation – Q2FY27 2 Company Overview Anlon at a Glance commercialised products 4 dedicated R&D laboratories under lab testing fume cupboards in pilot stage 105+ Workforce Strength 21 DMF’s Filed Globally 125+ Customers Served till date expected to commercialise - FY27 Countries Global Presence 3 CDMO Molecules 5 group entities across the Under development pharma value chain for 2 global innovator companies 60.7% Revenue: 1,900–2,000 MTPA (FY24-FY26 C A G R ) EBITDA: 75.3% Total Group Installed Capacity PAT: 73.6% Investor Presentation – Q2FY27 4 Business Overview • Established in 2013, Anlon Healthcare is a pharmaceutical company engaged in the manufacturing of APIs and pharmaceutical intermediates. • Anlon has built a strong presence in niche and specialty APIs, particularly NSAIDs, with its products serving diverse applications across pharmaceuticals, nutraceuticals, veterinary healthcare and personal care. • Over the years, Anlon has strengthened its backward-integrated API manufacturing capabilities, building a presence in niche and specialty products. • Recent acquisitions of Apiqo, Bizotic and Anlon Medicos have expanded its manufacturing base, backward integration and entry into formulations. • Anlon has further incorporated two new subsidiaries, Anlon Biologics and Anlon Medicare extending the platform into peptides, biosimilars and biological compositions, and into surgical implants for trauma, spine and joints. • Anlon is now evolving from an API-focused manufacturer into an integrated pharmaceutical platform, with growing presence across Industrial & Fine Chemicals → Intermediates → APIs → Formulations → Biologics & Medical Devices supported by a dedicated CDMO vertical serving global innovators. • Going forward, the business aims to drive growth through capacity expansion, CDMO commercialisation, new formulations and deeper vertical integration. • Anlon is scaling its presence in regulated export markets, targeting a materially higher export mix as DMF-backed products commercialise. • Anlon continues to strengthen its R&D and product development capabilities, supporting its expansion into new and higher-value pharmaceutical segments. Investor Presentation – Q2FY27 5 Product Portfolio & Core APIs A portfolio of 142 APIs and pharmaceutical intermediates, led by a core NSAID franchise in propionic-acid (profen) chemistry, serving pharmaceutical, nutraceutical, veterinary and personal care applications 49 Products under lab testing 28 Products in pilot stage 65 Commercialised products Early-stage development Scale-up and process In active commercial supply validation CORE COMMERCIALISED APIs A pain and anti-inflammatory drug used for osteoarthritis, rheumatoid arthritis and lower back pain. Loxoprofen Sodium Dihydrate Supplied in tablet and topical gel forms. NSAID – Prodrug Form A purified single-isomer form of ketoprofen that acts faster and at a lower dose. Used for acute pain, Dexketoprofen Trometamol particularly after surgery and for muscle and joint conditions. Supplied in tablet and injectable forms. NSAID – Single-Enantiomer Salt Ketoprofen / Ketoprofen A widely used painkiller and anti-inflammatory for arthritis, musculoskeletal pain and fever. Supplied Lysinate across tablet, topical gel and injectable forms. NSAID – Parent & Lysine Salt Among the few Indian manufacturers of loxoprofen, ketoprofen and dexketoprofen - molecules with a concentrated global supplier base and high regulatory barriers to entry. Investor Presentation – Q2FY27 6 Domestic Roots, Global Reach Global Presence India Presence Anlon Medicare Russia Canada UK Denmark Poland Germany Ukraine Slovakia Switzerland Moldova Croatia Romania USA Spain Italy Albania TuA rkrm eyenia South Korea Lebanon China Iraq Japan Israel Pakistan Taiwan Mexico Saudi ArabiaUAE Hong Kong Oman Cambodia Geographical Panama Nigeria Sri Lanka Vietnam Venezuela Revenue H1 FY27 (%) Australia South Africa Anlon Biologics New Zealand Export Domestic Strategically located group entities, strengthening supply-chain efficiency and global co [Showing first 8,000 characters — download PDF for full document]